Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Stopped The study was terminated because the first Phase 3 did not demonstrate efficacy on the co-primary endpoints. The known safety profile remained unchanged.

Conditions

• Alzheimer´s Disease

Interventions

• DRUG: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

Sponsor

Baxalta now part of Shire